Caris Life Sciences, Inc. (CAI) Guidance & Earnings Results
On 2026-08-05 Caris Life Sciences, Inc. raised guidance: "FY26 revenue guidance raised to $1.03-$1.04B from prior…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CAICaris Life Sciences, Inc.Follow CAI — free
—
Price chart with a free account
- Market cap
- 9.0B
- P/E TTM
- 85.6
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 5 Aug 26 | Raised | FY26 revenue guidance raised to $1.03-$1.04B from prior range · full year |
| 7 May 26 | Reaffirmed | FY2026 revenue $1.0B-$1.02B (23-26% growth); volume growth ~20% · full year |
| 26 Feb 26 | Raised | FY2026 revenue guidance $1.0B-$1.02B vs FY2025 $812M · full year |
| 5 Nov 25 | Raised | FY2025 revenue guidance raised to $720-$730M from prior range (not stated), representing 75-77% YoY growth · full year |
| 12 Aug 25 | Raised | FY2025 revenue raised to $675-685M (64-66% growth); clinical therapy selection volume growth 19-21% · full year |
Caris Life Sciences, Inc. — questions
- What guidance did Caris Life Sciences, Inc. give?
- On 2026-08-05: "FY26 revenue guidance raised to $1.03-$1.04B from prior range"
- When does Caris Life Sciences, Inc. report earnings?
- Caris Life Sciences, Inc.'s next earnings report is expected on 2026-11-04.
Every figure on this page comes from Caris Life Sciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.